Source: PHARMAC
Information on what the Cancer Treatments Advisory Committee (CTAC) will be considering at its upcoming meeting in April 2026.
Applications
Alectinib ECOG status change
The Committee will discuss recent feedback and seek advice on widening access to alectinib for first line treatment of people with poorer Eastern Cooperative Oncology Group Performance Status (ECOG) being treated for non-small cell lung cancer (ALK-positive).
First line treatment for the group with a better ECOG status has been funded since 2019.
Application for alectinib for NSCLC (ALK positive) first line (funded)(external link)
2019 funding decision, including alectinib (Alecensa)(external link)
Alectinib (branded as Alecensa) for non-small cell lung cancer (NSCLC)
The Committee will discuss an application for alectinib for people with resected (had surgery to remove the cancer), anaplastic lymphoma kinase-positive (ALK positive), non-small cell lung cancer (NSCLC).
Application for alectinib (Alecensa) for NSCLC(external link)
Durvalumab (branded as Imfinzi) for limited-stage, small cell lung cancer (LS-SMLC)
The Committee will discuss an application for durvalumab for people with limited stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
Application for Durvalumab (Imfinzi)(external link)
Inavolisib (branded as Itovebi) for breast cancer
The Committee will discuss an application for inavolisib for people with locally advanced or metastatic breast cancer, who have a PIK3K mutation, are HR-positive, and HER2-negative, following recurrence during or within 12 months of completing adjuvant therapy.
Application for inavolisib (Itovebi)(external link)
Ibrutinib (branded as Imbruvica) for mantle cell lymphoma
The Committee will discuss an application for ibrutinib for people with mantle cell lymphoma that are eligible for autologous stem cell transplant (ASCT). This is being considered as an alternative therapy to ASCT.
Application for Ibrutinib (Imbruvica)(external link)
Blinatumomab (branded as Blinctyo) for acute lymphoblastic leukaemia (ALL)
The Committee will discuss an application for blinatumomab for people with B cell lineage acute lymphoblastic leukaemia (ALL), who do not have measurable residual disease (MRD-negative).
